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OBJECTIVES: To present a case study of Bayesian approach to performance-based 
pricing in Japan, and to discuss advantages and limitations of the proposed method. 
METHODS: The ofﬁ cial price of any new drug listed on the National Reimbursement 
List in Japan is initially determined by Ministry of Health, Labor, and Welfare in 
political manners with some equations historically developed without considering the 
science of pharmacoeconomics. The initial price determined when approved is bien-
nially re-priced downward regarding the average market price (AMP) in reality. At 
ﬁ rst, we reviewed the pricing and re-pricing methods of the government, then identiﬁ ed 
which portion of the current rules for pricing and re-pricing could be reworded with 
the quantitative methods of biostatistics and pharmacoeconomics, and ﬁ nally tried to 
develop a Bayesian method for making the current re-pricing rule better quantiﬁ ed 
incorporating performance and value of a drug. RESULTS: We identiﬁ ed three por-
tions such as premium rule in pricing, an adjustment in re-pricing, and the market 
extension premium in re-pricing could be objectively described by scientiﬁ c methods. 
We developed in theory: 1) a pharmacoeconomic method associating the premium in 
pricing with ICER (incremental cost-effectiveness ratio); 2) a Bayesian method quan-
tifying an adjustment in the current re-pricing rule with respect to estimating the AMP 
according to the degree of Bayesian belief; and 3) a mixture method of Bayes and 
ICER quantifying the market extension in re-pricing to incorporate the performance-
based concept. CONCLUSIONS: The Japanese pricing and re-pricing rules, which 
employs the performance-based concept in a subjective manner, could be improved in 
terms of pharmacoeconomics and Bayesian statistics. Although the validation of the 
theory including data availability is left for further investigation, our approach would 
be thought-provoking for any country which considers a statistical approach to poli-
cymaking for performance-based pricing or reimbursement.
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OBJECTIVES: The number of risk-sharing schemes in the UK increased signiﬁ cantly 
since the introduction of the new Pharma Pricing and Regulation Scheme (PPRS) in 
early 2009. Other health-care systems seem to follow. The objective is to investigate 
via qualitative research if payers in Germany and The Netherlands are inﬂ uenced by 
UK decisions, if there are any preferred schemes, e.g., ﬁ nance-based versus value-
based, and if the outcome for payers and manufacturers are comparable among the 
countries concerned. METHODS: A comprehensive questionnaire was designed, vali-
dated, and translated into German and Dutch. Decision-makers at various levels 
involved in the implementation of risk-sharing models in Germany and The Nether-
lands were interviewed face to face. The interviews lasted approximately 60 minutes 
and were held in their mother language. All interviews were recorded and a total of 
n = 10 interviews were conducted. RESULTS: German payers especially sick funds 
seem to be more open to adopt risk-sharing models than their colleagues in The 
Netherlands. There is a clear tendency in both countries that UK risk-sharing schemes 
have an inﬂ uence on the decision-making process; however, most payers responded 
that there must be some adaptations to local needs. CONCLUSIONS: Risk-sharing 
models will become increasingly popular in the near future especially in Germany. 
Companies have to be prepared especially in therapeutic areas like oncology to follow 
this route as a way of market access. Although risk-sharing models have been intro-
duced in other European countries before 2009, the UK models seem to represent a 
benchmark among payers especially with regard to their transparency. 
PODIUM SESSION II: ADHERENCE AND COMPLIANCE STUDIES
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OBJECTIVES: Schizophrenia is a major psychotic disorder that has devastating effects 
on the lives of patients and their caregivers. Poor adherence to antipsychotic treatment 
is a well-recognized challenge among patients with schizophrenia and is associated 
with increased morbidity and consumption of health-care resources. Implementation 
of innovative strategies to enhance adherence is needed. To evaluate the effect of daily 
short message service (SMS) reminders on patients’ adherence to antipsychotic treat-
ment in schizophrenia. METHODS: A multicenter, randomized, open-label, con-
trolled trial. The study included clinically stabilized schizophrenic outpatients with 
adherence problems (at least one afﬁ rmative answer of Morisky–Green question-
naire—MAQ). Participants were randomized to receive a daily SMS reminder on their 
cell phone to take their medication in the following 3 months or current standard of 
care. The SMS reminder was sent daily at 10 am or 2 pm according to participants’ 
preferences. The primary end point was the absolute difference in mean adherence 
rate between the two groups after 3 months using MAQ. RESULTS: A total of 254 
patients were analyzed, 66.5% men. Mean age: 39.7 years (SD = 11.03). Baseline 
sociodemographic and clinical characteristics were similar between the two groups. 
No signiﬁ cant differences in baseline mean MAQ score were observed between groups 
(2.23, SD = 0.94 and 2.23, SD = 0.85, respectively). At month 3, mean MAQ score 
in the intervention group was 1.2 and 1.53 in the control group. The absolute differ-
ence in mean adherence rate between groups was −0.33 (95% CI −0.62, −0.03; P = 
0.03). Largest change from baseline was observed in question 4 of the questionnaire 
“When you feel better, do you sometimes stop taking your medicine?” (percentage of 
afﬁ rmative answers in the SMS group vs. control was 45% and 59%, respectively, P 
= 0.02). CONCLUSIONS: SMS reminders may help many patients become sufﬁ ciently 
adherent to their antipsychotic medication in addition to standard interventions for 
schizophrenia control.
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OBJECTIVES: Poor persistence to prescribed treatment regimens is a well-documented 
health problem. The issue is of particular importance in treatment of chronic diseases, 
such as osteoporosis. The objective of this study was to estimate the annual societal 
burden of real-world persistence to treatment of osteoporosis in Sweden. a second aim 
was to estimate the monetary net beneﬁ t of improved persistence. METHODS: The 
annual societal burden was evaluated in relation to perfect persistence to a 5-year 
treatment duration and performed using a published Markov model by Ström and 
colleagues. The target population was extracted from the Swedish Prescription Reg-
ister and based on all treatment-naïve patients who started therapy of primary osteo-
porosis in Sweden during 2009. Five hypothetical interventions were investigated, with 
improvements in the persistent proportion of between 10% and 50%. RESULTS: 
Annually, a total of 1018 fractures were estimated to be caused by nonpersistence to 
treatment of osteoporosis in Sweden. These fractures resulted in a substantial waste 
of health-care resources related to morbidity (c26 million annually) and a loss, in total, 
of 771 QALYs. Using a societal willingness-to-pay for a QALY of c60,000, the total 
annual societal burden, incorporating both monetary consequences and health effects, 
was estimated at c62.76 million. Given current Swedish cost-effectiveness guidelines, 
between approximately c225 and c1130 could be spent per patient to increase persis-
tence, depending on the level of improvement (between 10% and 50%). CONCLU-
SIONS: The total annual societal burden of current, real-world persistence was 
estimated at c63 million. The estimated additional fracture-related costs associated 
with poor persistence were larger than the current total annual expenditure on all 
osteoporosis medications in Sweden. Poor persistence to treatment of osteoporosis 
should consequently be acknowledged as an important and costly health problem, and 
be taken into account when evaluating osteoporosis interventions.
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Incorporating adherence in a health-economic evaluation is challenging. a novel con-
ceptual framework was developed that captures the multidimensional aspect of adher-
ence in a health-economic model, by considering the case of pain medication in chronic 
nonmalignant pain management. a 1-year microsimulation model was built. Realistic 
dosing proﬁ les (combining dose-taking and dose-timing information) were obtained 
from electronically compiled dosing histories gathered in the Aardex/Pharmionic data-
base. Probability and timing of dosing depended on time of intake during the day, 
day of the week, whether or not a previous dosage was taken, and number of days 
on treatment. The effect of dosages taken on pain was modeled via a pharmacoki-
netic–pharmacodynamic (PK-PD) model. The PK model translated dosages taken into 
drug concentration levels. Drug concentration levels inﬂ uenced the amount of pain a 
patient experienced, quantiﬁ ed by the PD model. Quality of life (QoL) values were 
obtained by assigning a utility value to the pain intensity a patient experienced. 
Dosages taken by the patient contributed to medication costs. Work productivity 
losses due to pain exacerbations, based on a pain survey, were included. The model 
simulated 1000 unique patients to generate stable results, comparing realistic dosing 
proﬁ les with an optimal dosing proﬁ le for a four times daily (QID) regimen. The 
realistic QID regimen had 14% lower average drug concentration levels and more 
than 3.5-fold higher standard deviation in concentration levels than the optimal 
regimen. Due to lower average concentration levels and higher ﬂ uctuation, this trans-
